Does Tigecycline Raise Transaminase Levels?
Yes, tigecycline, an intravenous glycylcycline antibiotic used for complicated infections, can increase transaminase levels (ALT and AST). This occurs in 1-15% of patients, typically as mild, transient elevations that resolve after treatment ends.[1][2]
How Common Are Transaminase Elevations?
Clinical trials report:
- ALT increases >3x upper limit of normal (ULN) in up to 15% of patients.
- AST increases >3x ULN in up to 8%.
Hepatobiliary lab abnormalities appear dose-related and more frequent in shorter trials (≤14 days).[1][3] Post-marketing data notes rare severe cases, including hepatitis and liver failure, but causality is unclear.[2]
Why Does This Happen?
Tigecycline disrupts bacterial protein synthesis but may stress hepatocytes via mitochondrial inhibition or direct toxicity. Elevations often lack symptoms and correlate with longer exposure or comorbidities like fatty liver disease.[3][4] No clear link to tigecycline's metabolism (primarily biliary excretion) explains it fully.
What Do Patients Experience?
Most cases are asymptomatic, detected via routine labs. Severe reactions (e.g., jaundice, cholestasis) are rare (<1%) and reversible upon discontinuation. Monitor LFTs weekly during therapy, especially in liver-impaired patients.[1][2]
Who Is at Higher Risk?
- Pre-existing liver disease.
- Prolonged therapy (>14 days).
- Concomitant hepatotoxins (e.g., other antibiotics, statins).
Adjust dose in moderate-severe hepatic impairment; avoid in Child-Pugh C.[1][4]
How Does Tigecycline Compare to Other Antibiotics?
Tigecycline shows higher transaminase elevations than beta-lactams (e.g., piperacillin-tazobactam: <5%) but similar to tetracyclines. Versus vancomycin or linezolid, it's intermediate. Pancreatitis risk is also elevated (1-2%).[3][5]
Management and Monitoring Guidelines
Discontinue if ALT/AST >5x ULN with symptoms or >10x ULN. FDA label recommends baseline and periodic LFTs. No routine prophylaxis needed.[1][2]
When Does It Resolve?
Elevations peak mid-therapy and normalize within 7-14 days post-treatment in 90% of cases.[3]
Sources
[1]: Tigecycline FDA Label
[2]: Tygacil Prescribing Information
[3]: Clinical Trial Data - Lancet Infect Dis
[4]: Hepatotoxicity Review - J Antimicrob Chemother
[5]: Antibiotic Hepatotoxicity Comparison - Hepatology